Shares of Intellia Therapeutics (NASDAQ: NTLA) climbed 8% on Tuesday following the company's announcement that the U.S. Food and Drug Administration has accepted its Biologics License Application (BLA) for lonvoguran ziclumeran, known as lonvo-z, and granted the submission Priority Review for the treatment of hereditary angioedema (HAE).
The agency set a Prescription Drug User Fee Act target action date of March 10, 2027. In its communication to the company, the FDA said it is not currently planning to convene an advisory committee to examine the application. If the BLA is approved, lonvo-z would represent the world's first in vivo CRISPR-based therapy and would be the only one-time treatment option for HAE.
The regulatory filing is supported by data from Intellia's Phase 3 HAELO clinical trial. HAELO enrolled 80 patients over a nine-month period and studied the efficacy and safety of a one-time 50 milligram dose of lonvo-z in adults and adolescents aged 16 years and older with Type 1 or Type 2 hereditary angioedema.
According to the trial results cited in the submission, HAELO met its primary endpoint and all key secondary endpoints. The study demonstrated an 87% reduction in mean monthly attacks for patients treated with lonvo-z compared with placebo during the efficacy evaluation period spanning weeks 5 through 28.
Additional efficacy findings showed that 62% of patients in the lonvo-z arm were both attack free and free of HAE therapy during the six-month efficacy evaluation period, compared with 11% of patients receiving placebo. The company reported that as of the February 10, 2026 data cutoff, all patients who had received lonvo-z at baseline or who crossed over to lonvo-z after week 28 remained free from long-term prophylaxis therapy.
The safety profile described in the BLA indicates certain treatment-emergent adverse events (TEAEs) occurred more frequently in the lonvo-z group than in the placebo group during the primary observation period. Those events included infusion-related reactions, headache, fatigue, back pain, and upper respiratory tract infection. Intellia reported that all TEAEs observed in the lonvo-z arm were classified as mild or moderate, and no serious adverse events were observed in that treatment group.
Summary of regulatory and clinical milestones
- FDA accepted Intellia's BLA for lonvo-z with Priority Review.
- PDUFA target action date set for March 10, 2027; no advisory committee currently planned.
- Phase 3 HAELO met primary and all key secondary endpoints, with an 87% reduction in mean monthly attacks versus placebo.
Context and market reaction
The FDA's acceptance of the BLA and Priority Review designation was followed by an immediate positive move in Intellia's stock price. The company's submission relies on the HAELO dataset, which enrolled 80 participants and tested a single 50 mg dose in patients 16 years and older with Type 1 or Type 2 HAE. The efficacy and safety findings cited in the filing are key to the agency's review ahead of the March 10, 2027 action date.
Key points
- Regulatory milestone: FDA accepted the BLA for lonvo-z with a March 10, 2027 target action date and does not currently plan an advisory committee - impacts biotech regulatory oversight and investor sentiment in biotech and pharma markets.
- Clinical results: HAELO showed an 87% reduction in mean monthly HAE attacks and 62% of treated patients were attack and therapy free over six months - directly relevant to HAE treatment paradigms and specialty care.
- Market reaction: NTLA shares rose following the BLA acceptance - relevant to healthcare equities and broader biotech investor activity.
Risks and uncertainties explicitly supported by the filing
- Regulatory outcome remains uncertain despite BLA acceptance - final approval is not guaranteed and depends on FDA review through the March 10, 2027 action date.
- Safety profile showed higher rates of certain treatment-emergent adverse events in the lonvo-z arm compared with placebo, including infusion-related reactions and upper respiratory tract infection; all were reported as mild or moderate.
- The Phase 3 HAELO dataset comprises 80 enrolled patients - the trial size is a factual parameter of the evidence supporting the BLA and relevant to assessment of the dataset.
Intellia's BLA acceptance marks a pivotal regulatory step for lonvo-z and for in vivo CRISPR approaches more broadly. The FDA's review over the coming months will determine whether the therapy can become the first one-time, in vivo CRISPR-based treatment for patients with hereditary angioedema.